Obesity and non-alcoholic fatty liver disease: therapeutic options

Kaschenko, V.A.; Mitsinskaya, A.I.; Sokolov, Alexey Y.; Шишкин, А Н; Варзин, С А; Neimark, A. E.; Mehtiyev, S N; Lodygin, A.V.; Mitsinskiy, M.A.; Akhmetov, A.D.

doi:10.20333/2500136-2020-3-20-29

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The problem of diagnosing MAFLD remains quite relevant at the present stage of medicine, as well as further treatment and monitoring [14][15][16]. Consequently, the problem is complex, and therefore requires a meaningful algorithm for early diagnosis [17,18].…”

Section: Introductionmentioning

confidence: 99%

Novel Method for Quantifying Hepatic Steatosis in Patients With Metabolically Associated Fatty Liver Disease

Борсуков

Venidiktova

Borsukov

2022

IJIM

View full text Add to dashboard Cite

Introduction. The article presents an overview of novel complex algorithm based on methods of ultrasound steatometry, combined elastography and dual-energy X-ray absorbtiometry in “Whole body” mode in diagnostic and monitoring of metabolically associated fatty liver disease.The purpose of the study: to assess the possibility of quantitative ultrasound steatometry using in the detection and monitoring of metabolically associated fatty liver disease.Material and methods. 157 patients were examined. The main group consisted of 47 patients with liver steatosis; 45 patients with steatohepatitis and clinically insigniﬁcant liver ﬁbrosis (F0-F1); 32 patients with steatohepatitis and clinically signiﬁcant liver ﬁbrosis (F2-F3); 33 patients with focal hepatic steatosis. We used complex algorithm based on methods of questionnaires, laboratory tests, ultrasound steatometry, combined elastography and dual-energy x-ray absorbtiometry in “Whole body” mode, liver biopsy. to determine the severity of steatosis, a scale was used: S0 – no steatosis; 2.9 dB/cm.Results and conclusion. It is possible to use quantitative ultrasound steatometry for metabolically associated fatty liver disease, as a reference method both for the initial detection of the disease and for monitoring non-drug treatment (sensitivity 90.7%, speciﬁcity 92.4%). The optimal complex for the diagnosis and monitoring of non-drug treatment of metabolically associated fatty liver disease includes an assessment of the level of compliance, the use of quantitative ultrasound steatometry and dual-energy X-ray absorptiometry in the «Whole body» mode (sensitivity 92.8%, speciﬁcity 92.3%).

show abstract

Section: Introductionmentioning

confidence: 99%

Novel Method for Quantifying Hepatic Steatosis in Patients With Metabolically Associated Fatty Liver Disease

Борсуков

Venidiktova

Borsukov

2022

IJIM

View full text Add to dashboard Cite

show abstract

Possibilities for the use of ursodeoxycholic acid in the treatment of patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease

Rasskazova,

Vorobyev,

Butova

2023

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Aim. To investigate the effect of ursodeoxycholic acid (UDCA) on the degree of steatosis, indicators of carbohydrate, lipid metabolism, body weight in patients with type 2 diabetes mellitus (DM) in combination with non-alcoholic fatty liver disease (NAFLD). Materials and methods. A prospective cohort comparative study included 36 patients with DM and NAFLD. Patients received UDCA at a dose of 15 mg/kg/day for 6 months, and also followed the recommendations for lifestyle changes through diet and exercise. To compare the results obtained during the study, a control group of patients was recruited that met the criteria for inclusion in the study. The statistical analysis included an assessment of the normality of the distribution of quantitative indicators, followed by the determination of the mean values and standard deviation or medians and quartiles, depending on the nature of the distribution, the reliability coefficient was determined by the Student, by Wilcoxon. Statistical processing was carried out in the Statistica 10 program. Results. According to the results of the study, a positive trend was noted in the change in the severity of fatty hepatosis. During the study, a statistically significant decrease in the level of ALT, AST was achieved in the group receiving UDCA (Ursofalk). The results of our study showed that the inclusion of UDCA (Ursofalk) in complex hypoglycemic therapy provides an additional improvement in carbohydrate metabolism. The obtained indicators in the course of the study demonstrate the positive effect of UDCA on weight loss. The greatest result was achieved in reducing waist, which is a positive prognostic factor in reducing the development and progression of NAFLD, diabetes and cardiovascular diseases. Positive changes were observed in relation to the lipid profile. Conclusion. The study demonstrated the positive effect of the drug UDCA (Ursofalk) on reducing the degree of liver steatosis, on carbohydrate, lipid metabolism, body weight in patients with DM in combination with NAFLD.

show abstract

Obesity and non-alcoholic fatty liver disease: therapeutic options

Cited by 2 publications

References 0 publications

Novel Method for Quantifying Hepatic Steatosis in Patients With Metabolically Associated Fatty Liver Disease

Novel Method for Quantifying Hepatic Steatosis in Patients With Metabolically Associated Fatty Liver Disease

Possibilities for the use of ursodeoxycholic acid in the treatment of patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease

Contact Info

Product

Resources

About